SCHEMBL1749775

SCHEMBL1749775

CC(=O)CNC1CCN(c2ccc(NC(=O)c3ccc(S(=O)(=O)c4ccccc4)cc3)cc2)C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 7/20 0.59
KMT2A Q03164 3/20 0.54
MAPT P10636 3/20 0.54
KDM4E B2RXH2 1/20 0.54
LMNA P02545 1/20 0.54
MAPK1 P28482 1/20 0.54
MEN1 O00255 2/20 0.52
HPGD P15428 1/20 0.52
PRMT1 Q99873 3/20 0.48
NAMPT P43490 2/20 0.47
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 1/20 0.47
PKM P14618 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
SETD7 Q8WTS6 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749779 0.87 MCHR1 (0.48) MCHR1KMT2AMAPTKDM4ELMNA
SCHEMBL1749538 0.86 MCHR1 (0.60) MCHR1KMT2AMAPTKDM4EMEN1
SCHEMBL1749126 0.83 MAPT (0.65) MCHR1KMT2AMAPTKDM4ELMNA
SCHEMBL1750063 0.81 MCHR1 (0.53) MCHR1KMT2AMAPTKDM4ELMNA
SCHEMBL1749776 0.81 MCHR1 (0.78) MCHR1KMT2AMAPTKDM4ELMNA
SCHEMBL12530190 0.81 MCHR1 (0.77) MCHR1KMT2AMAPTKDM4ELMNA
SCHEMBL1749100 0.80 MCHR1 (0.52) MCHR1KMT2AMAPTKDM4ELMNA
SCHEMBL1749222 0.79 MCHR1 (0.52) MCHR1KMT2AMAPTKDM4ELMNA
SCHEMBL1750162 0.79 MCHR1 (0.52) MCHR1KMT2AMAPTKDM4EMAPK1
SCHEMBL1749171 0.79 MAPT (0.63) MCHR1KMT2AMAPTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968550-B2 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2011-06-28 US disclosed
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 US disclosed
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments CYP11B2, CYP11B1, NQO1 MCHR1 2068/4885KMT2A 4320/4885MAPT 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.